Trial Profile

A Phase 1/2 Trial of ADI-270 (Engineered γ?? Chimeric Receptor [CAR] V??1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 May 2025 According to Adicet media release, the company expect to report preliminary Phase 1 data in the second half of 2025.
30 Apr 2025 Trial in progress poster presented at the 116th Annual Meeting of the American Association for Cancer Research.
03 Mar 2025 According to Adicet Bio media release, data from this study will be presented in a poster presentation by Gregory Vosganian, M.D. on Thursday, March 13, 2025, from 5:00 p.m. - 6:30 p.m. PT, at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com